Compare FICO & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FICO | MIST |
|---|---|---|
| Founded | 1956 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 95.3M |
| IPO Year | 1995 | 2019 |
| Metric | FICO | MIST |
|---|---|---|
| Price | $671.96 | $0.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 7 |
| Target Price | ★ $821.37 | $3.86 |
| AVG Volume (30 Days) | 700.9K | ★ 1.9M |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.85 | N/A |
| EPS | ★ 36.32 | N/A |
| Revenue | ★ $1,032,475,000.00 | N/A |
| Revenue This Year | $2.20 | $215.89 |
| Revenue Next Year | $6.47 | $157.01 |
| P/E Ratio | $18.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $595.19 | $0.36 |
| 52 Week High | $1,858.91 | $3.06 |
| Indicator | FICO | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 31.79 |
| Support Level | $662.30 | N/A |
| Resistance Level | $760.65 | $0.84 |
| Average True Range (ATR) | 33.72 | 0.08 |
| MACD | 1.41 | -0.03 |
| Stochastic Oscillator | 25.17 | 17.15 |
Founded in 1956, Fair Isaac is a leading applied analytics company. It is primarily known for its FICO credit scores, a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.